Curetis AG, a Holzgerlingen, Germany-based molecular diagnostics company focusing on the development and commercialization of invitro diagnostic products for infectious diseases, raised an additional funding as a part of its Series A financing.
This brings the total amount raised by Curetis in the round to € 24.5m.
In 2009, the company had raised €18.5m (read the news).
Investors include new backer CD-Venture and existing shareholders aeris CAPITAL, LSP (Life Sciences Partners), BioMedPartners and the ERP-Startfonds of the KfW Bankengruppe.
Curetis, which recently appointed Oliver Schacht, PhD, as new CEO, intends to use the funds to prepare for commercial launch and roll-out of its Unyvero product platform together with the CE marked IVD test cartridge for pneumonia and antibiotic resistances.
The Unyvero platform is a hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run.